Advancing Pharmacotherapy Development from Preclinical Animal Studies (original) (raw)

References

• Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37:504–508
  CAS PubMed Google Scholar
• Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D’Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915–1922
  CAS PubMed Google Scholar
• Addolorato G, Mirijello A, Leggio L (2013) Alcohol addiction: toward a patient-oriented pharmacological treatment. Expert Opin Pharmacother 14:2157–2160
  CAS PubMed PubMed Central Google Scholar
• Adinoff B, Martin PR, Bone GH, Eckardt MJ, Roehrich L, George DT, Moss HB, Eskay R, Linnoila M, Gold PW (1990) Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin releasing hormone and corticotropin levels in alcoholics after recent and long-term abstinence. Arch Gen Psychiatry 47(4):325–330
  CAS PubMed Google Scholar
• Adinoff B, Iranmanesh A, Veldhuis J, Fisher L (1998) Disturbances of the stress response: the role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res World 22(1):67–72
  CAS PubMed Google Scholar
• Alaux-Cantin S, Buttolo R, Houchi H, Jeanblanc J, Naassila M (2015) Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict Biol 20(5):890–901
  CAS PubMed Google Scholar
• Alén F, Orio L, Gorriti MÁ, de Heras RG, Ramírez-López MT, Pozo MÁ, de Fonseca FR (2013) Increased alcohol consumption in rats after subchronic antidepressant treatment. Int J Neuropsychopharmacol 16(8):1809–1818
  PubMed Google Scholar
• Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP (2016) GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65:54–66
  CAS PubMed Google Scholar
• Anderzhanova E, Kirmeier T, Wotjak CT (2017) Animal models in psychiatric research: the RDoC system as a new framework for endophenotype-oriented translational neuroscience. Neurobiol Stress 7:47–56
  PubMed PubMed Central Google Scholar
• Anthenelli RM, Heffner JL, Wong E, Tibbs J, Russell K, Isgro M, Dinh E, Wehrle C, Worley MJ, Doran N (2017) A randomized trial evaluating whether topiramate aids smoking cessation and prevents alcohol relapse in recovering alcohol-dependent men. Alcohol Clin Exp Res 41(1):197–206
  CAS PubMed Google Scholar
• Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24(4):421–428
  CAS PubMed Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017
  CAS PubMed Google Scholar
• Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J (2008a) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28:5–12
  CAS PubMed Google Scholar
• Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008b) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65(2):135–144
  CAS PubMed PubMed Central Google Scholar
• Arias A, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 30:318–322
  CAS PubMed PubMed Central Google Scholar
• Aujla H, Cannarsa R, Romualdi P, Ciccocioppo R, Martin-Fardon R, Weiss F (2013) Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal. Addict Biol 18(3):467–479
  CAS PubMed Google Scholar
• Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R (2005) The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 30:1104–1110
  CAS PubMed Google Scholar
• Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103(12):2035–2044
  PubMed Google Scholar
• Bartha PFA (2010) By parallel reasoning: the construction and evaluation of analogical arguments. Oxford University Press, New York
  Google Scholar
• Bartlett S, Heilig M (2013) Translational approaches to medication development. Curr Top Behav Neurosci 13:543–582
  CAS PubMed Google Scholar
• Beardsley PM, Lopez OT, Gullikson G, Flynn D (1994) Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol 11:389–395
  CAS PubMed Google Scholar
• Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, Becker HC (2015) Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol 20(1):38–42
  CAS PubMed Google Scholar
• Bender S, Scherbaum N, Soyka M, Rüther E, Mann K, Gastpar M (2007) The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharmacol 10(5):653–660
  CAS PubMed Google Scholar
• Besheer J, Lepoutre V, Hodge CW (2004) GABAB receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology 174:358–366
  CAS PubMed Google Scholar
• Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M (2016) Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. Neuropharmacology 101:216–224
  CAS PubMed Google Scholar
• Blaine SK, Sinha R (2017) Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders. Neuropharmacology 122:136–147
  CAS PubMed PubMed Central Google Scholar
• Blednov YA, Benavidez JM, Black M, Harris RA (2014) Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci 8:129
  PubMed PubMed Central Google Scholar
• Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, Durlach J (1984) A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 21(5):787–789
  CAS PubMed Google Scholar
• Boyle AE, Stewart RB, Macenski MJ, Spiga R, Johnson BA, Meisch RA (1998) Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys. Alcohol Clin Exp Res 22(2):359–366
  CAS PubMed Google Scholar
• Breslin FJ, Johnson BA, Lynch WJ (2010) Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology 207:529–534
  CAS PubMed Google Scholar
• Bruijnzeel AW, Small E, Pasek TM, Yamada H (2010) Corticotropin-releasing factor mediates the dysphoria-like state associated with alcohol withdrawal in rats. Behav Brain Res 210(2):288–291
  CAS PubMed PubMed Central Google Scholar
• Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287–301
  CAS PubMed Google Scholar
• Chick J, Aschauer H, Hornik K, Investigators Group (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 74(1):61–70
  CAS PubMed Google Scholar
• Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ (2007) Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 86(4):813–821
  CAS PubMed PubMed Central Google Scholar
• Ciccocioppo R, Panocka I, Polidori C, Regoli D, Massi M (1999) Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology 141(2):220–224
  CAS PubMed Google Scholar
• Ciccocioppo R, Polidori C, Antonelli L, Salvadori S, Guerrini R, Massi M (2002) Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides 23(1):117–125
  CAS PubMed Google Scholar
• Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, Massi M (2004) Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology 172(2):170–178
  CAS PubMed Google Scholar
• Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61(1):4–12
  CAS PubMed Google Scholar
• Ciccocioppo R, Stopponi S, Economidou D, Kuriyama M, Kinoshita H, Heilig M, Roberto M, Weiss F, Teshima K (2014) Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat. Neuropsychopharmacology 39(11):2601–2610
  CAS PubMed PubMed Central Google Scholar
• Cifani C, Guerrini R, Massi M, Polidori C (2006) Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats. Peptides 27(11):2803–2810
  CAS PubMed Google Scholar
• Cohen C, Perrault G, Sanger DJ (1998) Preferential involvement of D3 versus D2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats. Psychopharmacology 140(4):478–485
  CAS PubMed Google Scholar
• Coleman LG, Crews FT (2018) Innate immune signaling and alcohol use disorders. Handb Exp Pharmacol (in press)
  Google Scholar
• Colombo G, Serra S, Brunetti G, Vacca G, Carai MA, Gessa GL (2003) Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 70:105–108
  CAS PubMed Google Scholar
• Correia D, Martynhak BJ, Pereira M, Siba IP, Ribeiro AF, Camarini R, Boerngen-Lacerda R (2015) Reduction of ethanol intake by corticotropin-releasing factor receptor-1 antagonist in “heavy-drinking” mice in a free-choice paradigm. Psychopharmacology 232(15):2731–2739
  CAS PubMed Google Scholar
• Crabbe JC, Wahlsten D, Dudek BC (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284(5420):1670–1672
  CAS PubMed Google Scholar
• Crabbe JC, Ozburn AR, Metten P, Barkley-Levenson A, Schlumbohm JP, Spence SE, Hack WR, Huang LC (2017) High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. Pharmacol Biochem Behav 160:55–62
  CAS PubMed PubMed Central Google Scholar
• Crews FT, Lawrimore CJ, Walter TJ, Coleman LG Jr (2017) The role of neuroimmune signaling in alcoholism. Neuropharmacology 122:56–73
  CAS PubMed PubMed Central Google Scholar
• Cruz MT, Herman MA, Kallupi M, Roberto M (2012) Nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is enhanced after chronic ethanol exposure. Biol Psychiatry 71:666–676
  CAS PubMed Google Scholar
• Cservenka A, Courtney KE, Ghahremani DG, Hutchison KE, Ray LA (2017a) Development, initial testing and challenges of an ecologically valid reward prediction error fMRI task for alcoholism. Alcohol Alcohol 52(5):617–624
  PubMed PubMed Central Google Scholar
• Cservenka A, Yardley MM, Ray LA (2017b) Review: pharmacogenetics of alcoholism treatment: implications of ethnic diversity. Am J Addict 26(5):516–525
  PubMed Google Scholar
• Dautzenberg FM, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick GJ, Jenck F (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64–6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 298(2):812–819
  CAS PubMed Google Scholar
• Dayas CV, Liu X, Simms JA, Weiss F (2007) Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone. Biol Psychiatry 61(8):979–989
  CAS PubMed Google Scholar
• de Bejczy A, Löf E, Walther L, Guterstam J, Hammarberg A, Asanovska G, Franck J, Isaksson A, Söderpalm B (2015) Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol Clin Exp Res 39(11):2189–2199
  PubMed Google Scholar
• de Guglielmo G, Martin-Fardon R, Teshima K, Ciccocioppo R, Weiss F (2015) MT-7716, a potent NOP receptor agonist, preferentially reduces ethanol seeking and reinforcement in post-dependent rats. Addict Biol 20(4):643–651
  PubMed Google Scholar
• Doetkotte R, Opitz K, Kiianmaa K, Winterhoff H (2005) Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine. Eur J Pharmacol 522(1–3):72–77
  CAS PubMed Google Scholar
• Dongier M, Vachon L, Schwartz G (1991) Bromocriptine in the treatment of alcohol dependence. Alcohol Clin Exp Res 15(6):970–977
  CAS PubMed Google Scholar
• Donoghue K, Rose A, Coulton S, Milward J, Reed K, Drummond C, Little H (2016) Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry 16:40
  PubMed PubMed Central Google Scholar
• Duke AN, Kaminski BJ, Weerts EM (2014) Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. Addict Biol 19(1):16–26
  CAS PubMed Google Scholar
• Dundon W, Lynch KG, Pettinati HM, Lipkin C (2004) Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res 28(7):1065–1073
  CAS PubMed PubMed Central Google Scholar
• Duzzioni M, Duarte FS, Leme LR, Gavioli EC, De Lima TC (2011) Anxiolytic-like effect of central administration of NOP receptor antagonist UFP-101 in rats submitted to the elevated T-maze. Behav Brain Res 222(1):206–211
  CAS PubMed Google Scholar
• Economidou D, Fedeli A, Fardon RM, Weiss F, Massi M, Ciccocioppo R (2006) Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides 27(12):3299–3306
  CAS PubMed PubMed Central Google Scholar
• Economidou D, Hansson AC, Weiss F, Terasmaa A, Sommer WH, Cippitelli A, Fedeli A, Martin-Fardon R, Massi M, Ciccocioppo R, Heilig M (2008) Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 64(3):211–218
  CAS PubMed PubMed Central Google Scholar
• Economidou D, Cippitelli A, Stopponi S, Braconi S, Clementi S, Ubaldi M, Martin-Fardon R, Weiss F, Massi M, Ciccocioppo R (2011) Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat. Alcohol Clin Exp Res 35(4):747–755
  CAS PubMed PubMed Central Google Scholar
• Edwards S, Koob GF (2010) Neurobiology of dysregulated motivational systems in drug addiction. Future Neurol 5(3):393–401
  CAS PubMed PubMed Central Google Scholar
• Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF (2012) Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol 17(1):76–85
  CAS PubMed Google Scholar
• Edwards S, Little HJ, Richardson HN, Vendruscolo LF (2015) Divergent regulation of distinct glucocorticoid systems in alcohol dependence. Alcohol 49(8):811–816
  CAS PubMed PubMed Central Google Scholar
• Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E (2013) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38(8):1259–1270
  CAS PubMed Google Scholar
• Egli M (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10(4):309–319
  CAS PubMed Google Scholar
• Egli M, Koob GF, Edwards S (2012) Alcohol dependence as a chronic pain disorder. Neurosci Biobehav Rev 36(10):2179–2192
  PubMed PubMed Central Google Scholar
• Egli M, White DA, Acri JB (2016) Considerations in the evaluation of potential efficacy of medications for alcohol and drug use disorders: an editorial. Int Rev Neurobiol 126:1–14
  CAS PubMed Google Scholar
• Eisenhardt M, Hansson AC, Spanagel R, Bilbao A (2015) Chronic intermittent ethanol exposure in mice leads to an up-regulation of CRH/CRHR1 signaling. Alcohol Clin Exp Res 39(4):752–762
  CAS PubMed Google Scholar
• Evans SM, Levin FR, Brooks DJ, Garawi F (2007) A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 31(5):775–782
  CAS PubMed Google Scholar
• Fahlke C, Eriksson CJ (2000) Effect of adrenalectomy and exposure to corticosterone on alcohol intake in alcohol-preferring and alcohol-avoiding rat lines. Alcohol Alcohol 35(2):139–144
  CAS PubMed Google Scholar
• Fahlke C, Engel JA, Eriksson CJ, Hård E, Söderpalm B (1994) Involvement of corticosterone in the modulation of ethanol consumption in the rat. Alcohol 11(3):195–202
  CAS PubMed Google Scholar
• Farook JM, Lewis B, Littleton JM, Barron S (2009) Topiramate attenuates the stress-induced increase in alcohol consumption and preference in male C57BL/6J mice. Physiol Behav 96(1):189–193
  CAS PubMed Google Scholar
• Fawcett J, Kravitz HM, McGuire M, Easton M, Ross J, Pisani V, Fogg LF, Clark D, Whitney M, Kravitz G, Javaid J, Teas G (2000) Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 24(5):666–674
  CAS PubMed Google Scholar
• Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, Tompkins DA, Stout R, NCIG 002 Study Group (2012) A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 36(8):1421–1430
  CAS PubMed PubMed Central Google Scholar
• Fish EW, Agoglia AE, Krouse MC, Muller RG, Robinson JE, Malanga CJ (2014) Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice. Behav Pharmacol 25(1):61–70
  CAS PubMed Google Scholar
• Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W, Jaklitsch H, Sastre-y-Hernandez M (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26:59–64
  CAS PubMed Google Scholar
• Franklin KM, Hauser SR, Lasek AW, McClintick J, Ding ZM, McBride WJ, Bell RL (2015) Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4). Psychopharmacology 232(13):2251–2262
  CAS PubMed PubMed Central Google Scholar
• Froehlich JC, Harts J, Lumeng L, Li T-K (1990) Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 35:385–390
  CAS PubMed Google Scholar
• Froehlich JC, Nicholson ER, Dilley JE, Filosa NJ, Rademacher LC, Smith TN (2017) Varenicline reduces alcohol intake during repeated cycles of alcohol reaccess following deprivation in alcohol-preferring (P) rats. Alcohol Clin Exp Res 41(8):1510–1517
  CAS PubMed PubMed Central Google Scholar
• Funk CK, O’Dell LE, Crawford EF, Koob GF (2006) Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26(44):11324–11332
  CAS PubMed Google Scholar
• Funk D, Lo S, Coen K, Lê AD (2016) Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse. Behav Brain Res 296:157–162
  CAS PubMed Google Scholar
• Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(11):1691–1700
  CAS PubMed Google Scholar
• Garbutt JC, Kampov-Polevoi AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34:1849–1857
  CAS PubMed PubMed Central Google Scholar
• Gavioli EC, Calò G (2013) Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. Pharmacol Ther 140(1):10–25
  CAS PubMed Google Scholar
• Gehlert DR, Cippitelli A, Thorsell A, Lê AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M (2007) 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27(10):2718–2726
  CAS PubMed Google Scholar
• George DT, Rawlings R, Eckardt MJ, Phillips MJ, Shoaf SE, Linnoila M (1999) Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 23:272–278
  CAS PubMed Google Scholar
• George O, Sanders C, Freiling J, Grigoryan E, Vu S, Allen CD, Crawford E, Mandyam CD, Koob GF (2012) Recruitment of medial prefrontal cortex neurons during alcohol withdrawal predicts cognitive impairment and excessive alcohol drinking. Proc Natl Acad Sci 109(44):18156–18161
  CAS PubMed Google Scholar
• Gondré-Lewis MC, Warnock KT, Wang H, June HL Jr, Bell KA, Rabe H, Tiruveedhula VV, Cook J, Lüddens H, Aurelian L, June HL Sr (2016) Early life stress is a risk factor for excessive alcohol drinking and impulsivity in adults and is mediated via a CRF/GABA(A) mechanism. Stress 19(2):235–247
  PubMed PubMed Central Google Scholar
• Gong MF, Wen RT, Xu Y, Pan JC, Fei N, Zhou YM, Xu JP, Liang JH, Zhang HT (2017) Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents. Psychopharmacology 234(20):3143–3151. https://doi.org/10.1007/s00213-017-4697-3
  Article CAS PubMed Google Scholar
• Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, Heilig JS (2013) Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J Comp Neurol 521(10):2235–2261
  CAS PubMed Google Scholar
• Gubner NR, McKinnon CS, Phillips TJ (2014) Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization. Alcohol Clin Exp Res 38(12):3033–3042
  CAS PubMed PubMed Central Google Scholar
• Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Björk K, Soverchia L, Terasmaa A, Massi M, Heilig M, Ciccocioppo R (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci 103(41):15236–15241
  CAS PubMed Google Scholar
• Harris RA, Bajo M, Bell RL, Blednov YA, Varodayan FP, Truitt JM, de Guglielmo G, Lasek AW, Logrip ML, Vendruscolo LF, Roberts AJ, Roberts E, George O, Mayfield J, Billiar TR, Hackam DJ, Mayfield RD, Koob GF, Roberto M, Homanics GE (2017) Genetic and pharmacologic manipulation of TLR4 has minimal impact on ethanol consumption in rodents. J Neurosci 37(5):1139–1155
  CAS PubMed PubMed Central Google Scholar
• Hedlund L, Wahlström G (1996) Buspirone as an inhibitor of voluntary ethanol intake in male rats. Alcohol Alcohol 31(2):149–156
  CAS PubMed Google Scholar
• Hedlund L, Wahlström G (1999) Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism. Alcohol Clin Exp Res 23(5):822–827
  CAS PubMed Google Scholar
• Heilig M, Leggio L (2016) What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res 224:401–418
  PubMed Google Scholar
• Heilig M, Goldman D, Berrettini W, O’Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12(11):670–684
  CAS PubMed PubMed Central Google Scholar
• Heilig M, Sommer WH, Spanagel R (2016) The need for treatment responsive translational biomarkers in alcoholism research. Curr Top Behav Neurosci 28:151–171
  CAS PubMed Google Scholar
• Helms CM, McClintick MN, Grant KA (2012) Social rank, chronic ethanol self-administration, and diurnal pituitary-adrenal activity in cynomolgus monkeys. Psychopharmacology 224(1):133–143
  CAS PubMed PubMed Central Google Scholar
• Hempel CG (1965) Aspects of scientific explanation. In: Aspects of scientific explanation and other essays in the philosophy of science. Free Press, New York, pp 331–496
  Google Scholar
• Hesse MB (1966) Models and analogies in science. University of Notre Dame Press, Notre Dame
  Google Scholar
• Heyser CJ, Moc K, Koob GF (2003) Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 28:1463–1471
  CAS PubMed Google Scholar
• Hoel EP, Albantakis L, Tononi G (2013) Quantifying causal emergence shows that macro can beat micro. Proc Natl Acad Sci U S A 110(49):19790–19795
  CAS PubMed PubMed Central Google Scholar
• Hölter SM, Danysz W, Spanagel R (1996) Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314(3):R1–R2
  PubMed Google Scholar
• Hu W, Lu T, Chen A, Huang Y, Hansen R, Chandler LJ, Zhang HT (2011) Inhibition of phosphodiesterase-4 decreases ethanol intake in mice. Psychopharmacology 218:331–339
  CAS PubMed PubMed Central Google Scholar
• Hwa LS, Debold JF, Miczek KA (2013) Alcohol in excess: CRF1 receptors in the rat and mouse VTA and DRN. Psychopharmacology 225(2):313–327
  CAS PubMed Google Scholar
• Ingman K, Kupila J, Hyytiä P, Korpi ER (2006) Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41(4):391–398
  CAS PubMed Google Scholar
• Jacquot C, Croft AP, Prendergast MA, Mulholland P, Shaw SG, Little HJ (2008) Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption. Alcohol Clin Exp Res 32(12):2107–2116
  CAS PubMed Google Scholar
• Jaeger RG, Halliday TR (1998) On confirmatory versus exploratory research. Herpetologica 54:S64–S66
  Google Scholar
• Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C (1996) Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 128(2):206–215
  CAS PubMed Google Scholar
• Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963–971
  CAS PubMed Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677–1685
  CAS PubMed Google Scholar
• Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift R (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651
  CAS PubMed Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168(3):265–275
  PubMed PubMed Central Google Scholar
• Jones JD, Comer SD, Kranzler HR (2015) The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res 39(3):391–402
  PubMed PubMed Central Google Scholar
• June HL, Cummings R, Eiler WJA II, Foster KL, McKay PF, Seyoum R, Garcia M, McCane S, Grey C, Hawkins SE, Mason D (2004) Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol preferring (P) rats. Neuropsychopharmacology 29:285–299
  CAS PubMed Google Scholar
• Kalin NH, Fox AS, Kovner R, Riedel MK, Fekete EM, Roseboom PH, Tromp DP, Grabow BP, Olsen ME, Brodsky EK, McFarlin DR, Alexander AL, Emborg ME, Block WF, Fudge JL, Oler JA (2016) Overexpressing corticotropin-releasing factor in the primate amygdala increases anxious temperament and alters its neural circuit. Biol Psychiatry 80:345–355
  CAS PubMed PubMed Central Google Scholar
• Kallupi M, Scuppa G, de Guglielmo G, Calò G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R (2017) Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction. Neuropsychopharmacology 42(3):695–706
  CAS PubMed Google Scholar
• Kaminski BJ, Weerts EM (2014) The effects of varenicline on alcohol seeking and self-administration in baboons. Alcohol Clin Exp Res 38(2):376–383
  CAS PubMed Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O’Brien CP (2007) A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 27(4):344–351
  CAS PubMed PubMed Central Google Scholar
• Kaye JT, Bradford DE, Magruder KP, Curtin JJ (2017) Probing for neuroadaptations to unpredictable stressors in addiction: translational methods and emerging evidence. J Stud Alcohol Drugs 78(3):353–371
  PubMed PubMed Central Google Scholar
• Kimmelman J, Mogil JS, Dirnagl U (2014) Distinguishing between exploratory and confirmatory preclinical research will improve translation. PLoS Biol 12(5):e1001863
  PubMed PubMed Central Google Scholar
• Kimpel MW, Strother WN, McClintick JN, Carr LG, Liang T, Edenberg HJ, McBride WJ (2007) Functional gene expression differences between inbred alcohol-preferring and-non-preferring rats in five brain regions. Alcohol 41(2):95–132
  CAS PubMed PubMed Central Google Scholar
• Knapp CM, Mercado M, Markley T, Crosby S, Ciraulo DA, Kornetsky C (2007) Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav 87:65–72
  CAS PubMed PubMed Central Google Scholar
• Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35(1):34–42
  CAS PubMed Google Scholar
• Koenig HN, Olive MF (2004) The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions. Psychoneuroendocrinology 29(8):999–1003
  CAS PubMed Google Scholar
• Koob GF (2015) The dark side of emotion: the addiction perspective. Eur J Pharmacol 753:73–87
  CAS PubMed PubMed Central Google Scholar
• Koob GF (2016) Corticotropin-releasing factor from rodents to primates: translational hope expresses itself, pun intended. Biol Psychiatry 80(5):340–342
  CAS PubMed PubMed Central Google Scholar
• Koob GF, Zimmer A (2012) Animal models of psychiatric disorders. Handb Clin Neurol 106:137–166
  PubMed Google Scholar
• Koob GF, Zorrilla EP (2012) Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology 37(1):308–309
  CAS PubMed Google Scholar
• Koob GF, Kenneth Lloyd G, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 8(6):500–515
  CAS PubMed PubMed Central Google Scholar
• Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ (1994) Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 51(9):720–731
  CAS PubMed Google Scholar
• Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152(3):391–397
  CAS PubMed Google Scholar
• Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24):1734–1739
  CAS PubMed Google Scholar
• Kuzmin A, Sandin J, Terenius L, Ogren SO (2003) Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 304(1):310–318
  CAS PubMed Google Scholar
• Kuzmin A, Kreek MJ, Bakalkin G, Liljequist S (2007) The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 32(4):902–910
  CAS PubMed Google Scholar
• Kuzmin A, Bazov I, Sheedy D, Garrick T, Harper C, Bakalkin G (2009) Expression of pronociceptin and its receptor is downregulated in the brain of human alcoholics. Brain Res 1305(Suppl):S80–S85
  CAS PubMed PubMed Central Google Scholar
• Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, Rio DE, Huestis M, Anizan S, Concheiro M, Sinha R, Heilig M (2015) The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40(5):1053–1063
  CAS PubMed Google Scholar
• Kwako LE, Momenan R, Grodin EN, Litten RZ, Koob GF, Goldman D (2017) Addictions neuroclinical assessment: a reverse translational approach. Neuropharmacology 122:254–264
  CAS PubMed PubMed Central Google Scholar
• Lamb RJ, Järbe TU (2001) Effects of fluvoxamine on ethanol-reinforced behavior in the rat. J Pharmacol Exp Ther 297(3):1001–1009
  CAS PubMed Google Scholar
• Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Ritchie T, Noble EP (1995) Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1(4):337–341
  CAS PubMed Google Scholar
• Le Magnen J, Tran G, Durlach J, Martin C (1987) Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 4(2):97–102
  PubMed Google Scholar
• Lê AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21(3):435–344
  PubMed Google Scholar
• Lê AD, Funk D, Harding S, Juzytsch W, Fletcher PJ, Shaham Y (2006) Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats. Psychopharmacology 186:82–92
  PubMed Google Scholar
• Lê AD, Funk D, Coen K, Li Z, Shaham Y (2013) Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. Addict Biol 18(3):448–451
  PubMed Google Scholar
• Lee S, Rivier C (1997) An initial, three-day-long treatment with alcohol induces a long-lasting phenomenon of selective tolerance in the activity of the rat hypothalamic-pituitary-adrenal axis. J Neurosci 17(22):8856–8866
  CAS PubMed Google Scholar
• Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA (2015) A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology 232(1):233–243
  CAS PubMed Google Scholar
• Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M (2013) Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend 133(2):440–446
  CAS PubMed Google Scholar
• Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R, NCIG 001 Study Group (2012) A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 36(3):406–416
  CAS PubMed Google Scholar
• Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, Yi HY (2013a) The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 37(12):2128–2137
  CAS PubMed Google Scholar
• Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R, NCIG (2013b) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7:277–286
  CAS PubMed PubMed Central Google Scholar
• Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF (2015) Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res 39(4):579–584
  PubMed Google Scholar
• Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB (2016) Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abus 37(2):286–298
  PubMed Google Scholar
• Litten RZ, Falk DE, Ryan ML, Fertig J, Leggio L (2018) Advances in pharmacotherapy development: human clinical studies. Handb Exp Pharmacol (in press)
  Google Scholar
• Little HJ, Croft AP, O’Callaghan MJ, Brooks SP, Wang G, Shaw SG (2008) Selective increases in regional brain glucocorticoid: a novel effect of chronic alcohol. Neuroscience 156(4):1017–1027
  CAS PubMed Google Scholar
• Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22(18):7856–7861
  CAS PubMed Google Scholar
• Liu X, Hao PD, Yang MF, Sun JY, Mao LL, Fan CD, Zhang ZY, Li DW, Yang XY, Sun BL, Zhang HT (2017) The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice. Psychopharmacology 234(16):2409–2419
  CAS PubMed Google Scholar
• Logrip ML (2015) Phosphodiesterase regulation of alcohol drinking in rodents. Alcohol 49(8):795–802
  CAS PubMed PubMed Central Google Scholar
• Logrip ML, Zorrilla EP (2012) Stress history increases alcohol intake in relapse: relation to phosphodiesterase 10A. Addict Biol 17:920–933
  CAS PubMed PubMed Central Google Scholar
• Logrip ML, Zorrilla EP (2014) Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. Front Integr Neurosci 8:30
  PubMed PubMed Central Google Scholar
• Logrip ML, Vendruscolo LF, Schlosburg JE, Koob GF, Zorrilla EP (2014) Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology 39:1722–1731
  CAS PubMed PubMed Central Google Scholar
• Lu YL, Richardson HN (2014) Alcohol, stress hormones, and the prefrontal cortex: a proposed pathway to the dark side of addiction. Neuroscience 277:139–151
  CAS PubMed Google Scholar
• Lu SX, Higgins GA, Hodgson RA, Hyde LA, Del Vecchio RA, Guthrie DH, Kazdoba T, McCool MF, Morgan CA, Bercovici A, Ho GD, Tulshian D, Parker EM, Hunter JC, Varty GB (2011) The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8 azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species. Eur J Pharmacol 661(1–3):63–71
  CAS PubMed Google Scholar
• Lynch WJ, Bond C, Breslin FJ, Johnson BA (2011) Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology 217:3–12
  CAS PubMed PubMed Central Google Scholar
• Maccioni P, Zaru A, Loi B, Lobina C, Carai MA, Gessa GL, Capra A, Mugnaini C, Pasquini S, Corelli F, Hyytiä P, Lumeng L, Colombo G (2012) Comparison of the effect of the GABAB receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. Alcohol Clin Exp Res 36(10):1748–1766
  CAS PubMed PubMed Central Google Scholar
• Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16(6):1007–1013
  CAS PubMed Google Scholar
• Malec E, Malec T, Gagné MA, Dongier M (1996) Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 20(2):307–312
  CAS PubMed Google Scholar
• Malpass GE, Williams HL, McMillen BA (2010) Effects of the non-competitive NMDA receptor antagonist memantine on the volitional consumption of ethanol by alcohol-preferring rats. Basic Clin Pharmacol Toxicol 106(5):435–444
  CAS PubMed Google Scholar
• Mann K, Ackermann K, Diehl A, Ebert D, Mundle G, Nakovics H, Reker T, Richter G, Schmidt LG, Driessen M, Rettig K, Opitz K, Croissant B (2006) Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology 184(1):115–121
  CAS PubMed Google Scholar
• Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W (2016) Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol 26(12):1941–1949
  CAS PubMed Google Scholar
• Mardones J, Quintanilla ME (1996) Effects of bromocriptine on the voluntary consumption of ethanol, water, and solid food by UChA and UChB rats. Alcohol 13(4):355–357
  CAS PubMed Google Scholar
• Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Lê AD (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology 195(3):345–355
  CAS PubMed Google Scholar
• Martin-Fardon R, Ciccocioppo R, Massi M, Weiss F (2000) Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport 11(9):1939–1943
  CAS PubMed Google Scholar
• Mason BJ, Higley AE (2013) A translational approach to novel medication development for protracted abstinence. Curr Top Behav Neurosci 13:647–670
  CAS PubMed Google Scholar
• Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA 174:70–77
  CAS Google Scholar
• Maurel S, De Vry J, De Beun R, Schreiber R (1999) 5-HT2A and 5-HT2C/5-HT1B receptors are differentially involved in alcohol preference and consummatory behavior in cAA rats. Pharmacol Biochem Behav 62(1):89–96
  CAS PubMed Google Scholar
• McCaul ME, Wand GS, Weerts EM, Xu X (2017) A paradigm for examining stress effects on alcohol-motivated behaviors in participants with alcohol use disorder. Addict Biol. https://doi.org/10.1111/adb.12511
• McGeehan AJ, Olive MF (2003) The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. Br J Pharmacol 138(1):9–12
  CAS PubMed PubMed Central Google Scholar
• Meinhardt MW, Sommer WH (2015) Postdependent state in rats as a model for medication development in alcoholism. Addict Biol 20(1):1–21
  PubMed Google Scholar
• Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier G, Costentin J (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377(6549):532–535
  CAS PubMed Google Scholar
• Misra K, Pandey SC (2006) The decreased cyclic-AMP dependent protein kinase a function in the nucleus accumbens: a role in alcohol drinking but not in anxiety-like behaviors in rats. Neuropsychopharmacology 31:1406–1419
  CAS PubMed Google Scholar
• Mitchell JM, Grossman LE, Coker AR, Messing RO (2012a) The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol 32(2):269–272
  CAS PubMed Google Scholar
• Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012b) Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223:299–306
  CAS PubMed PubMed Central Google Scholar
• Möller C, Sommer W, Thorsell A, Rimondini R, Heilig M (2002) Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuro-Psychopharmacol Biol Psychiatry 26(1):119–122
  Google Scholar
• Müller CA, Geisel O, Petz P, Higl V, Kruger J, Stickel A, Beck A, Wernecke KD, Hellweg R, Heinz A (2015) High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25:1167–1177
  PubMed Google Scholar
• Mulligan MK, Ponomarev I, Hitzemann RJ, Belknap JK, Tabakoff B, Harris RA, Crabbe JC, Blednov YA, Grahame NJ, Phillips TJ, Finn DA, Hoffman PL, Iyer VR, Koob GF, Bergeson SE (2006) Toward understanding the genetics of alcohol drinking through transcriptome meta-analysis. Proc Natl Acad Sci U S A 103:6368–6373
  CAS PubMed PubMed Central Google Scholar
• Murphy NP (2010) The nociceptin/orphanin FQ system as a target for treating alcoholism. CNS Neurol Disord Drug Targets 9(1):87–93
  CAS PubMed Google Scholar
• Murphy JM, Waller MB, Gatto GJ, McBride WJ, Lumeng L, Li T-K (1988) Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. Alcohol 5:283–286
  CAS PubMed Google Scholar
• Nadal R, Prat G, Pallarés M, Hernández-Torres M, Ferré N (1996) Effects of bromocriptine on self-administration of sweetened ethanol solutions in rats. Psychopharmacology 128(1):45–53
  CAS PubMed Google Scholar
• Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 47(4):490–498
  CAS PubMed Google Scholar
• Naranjo CA, Dongier M, Bremner KE (1997) Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92(8):969–978
  CAS PubMed Google Scholar
• Narendran R, Ciccocioppo R, Lopresti B, Paris J, Himes ML, Mason NS (2017) Nociceptin receptors in alcohol use disorders: a positron emission tomography study using [(11)C]NOP-1A. Biol Psychiatry 17:31621–31629. https://doi.org/10.1016/j.biopsych.2017.05.019
  Article CAS Google Scholar
• Ng GY, George SR (1994) Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse. Eur J Pharmacol 269(3):365–374
  CAS PubMed Google Scholar
• Nirogi R, Kandikere V, Jayarajan P, Bhyrapuneni G, Saralaya R, Muddana N, Abraham R (2013) Aripiprazole in an animal model of chronic alcohol consumption and dopamine D2 receptor occupancy in rats. Am J Drug Alcohol Abuse 39(2):72–79
  PubMed Google Scholar
• Norman KJ, Seiden JA, Klickstein JA, Han X, Hwa LS, DeBold JF, Miczek KA (2015) Social stress and escalated drug self-administration in mice I. Alcohol and corticosterone. Psychopharmacology 232(6):991–1001
  CAS PubMed Google Scholar
• O’Brien ES, Legastelois R, Houchi H, Vilpoux C, Alaux-Cantin S, Pierrefiche O, André E, Naassila M (2011) Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. Neuropsychopharmacology 36(7):1518–1530
  PubMed Central Google Scholar
• O’Donnell JM, Marek GJ, Seiden LS (2005) Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 29(4–5):785–798
  PubMed Google Scholar
• Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132(5):1033–1044
  CAS PubMed PubMed Central Google Scholar
• Oberlin BG, Bristow RE, Heighton ME, Grahame NJ (2010) Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res 34(8):1363–1375
  CAS PubMed PubMed Central Google Scholar
• Oslin DW, Leong SH, Lynch KG, Berrettini W, O’Brien CP, Gordon AJ, Rukstalis M (2015) Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiat 72:430–437
  Google Scholar
• Osterndorff-Kahanek EA, Becker HC, Lopez MF, Farris SP, Tiwari GR, Nunez YO, Harris RA, Mayfield RD (2015) Chronic ethanol exposure produces time- and brain region-dependent changes in gene coexpression networks. PLoS One 10(3):e0121522
  PubMed PubMed Central Google Scholar
• Overmier JB, Patterson J (1988) Animal models of human psychopathology. Animal Models Psychiat Disord 1:1–35
  Google Scholar
• Pahng AR, McGinn MA, Paulsen RI, Edwards S (2017) The prefrontal cortex as a critical gate of negative affect and motivation in alcohol use disorder. Curr Opin Behav Sci 13:139–143
  PubMed PubMed Central Google Scholar
• Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F (2015) Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 12(12):e1001924
  PubMed PubMed Central Google Scholar
• Pandey SC, Zhang H, Roy A, Xu T (2005) Deficits in amygdaloid cAMP-responsive element-binding protein signaling play a role in genetic predisposition to anxiety and alcoholism. J Clin Invest 115:2762–2773
  CAS PubMed PubMed Central Google Scholar
• Phillips TJ, Reed C, Pastor R (2015) Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation. Genes Brain Behav 14(1):98–135
  CAS PubMed PubMed Central Google Scholar
• Piazza PV, Le Moal M (1997) Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Brain Res Rev 25(3):359–372
  CAS PubMed Google Scholar
• Plebani JG, Lynch KG, Rennert L, Pettinati HM, O’Brien CP, Kampman KM (2013) Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend 133(2):754–758
  CAS PubMed Google Scholar
• Pleil KE, Rinker JA, Lowery-Gionta EG, Mazzone CM, McCall NM, Kendra AM, Olson DP, Lowell BB, Grant KA, Thiele TE, Kash TL (2015) NPY signaling inhibits extended amygdala CRF neurons to suppress binge alcohol drinking. Nat Neurosci 18(4):545–552
  CAS PubMed PubMed Central Google Scholar
• Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A (2015) Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abus Treat 52:24–30
  Google Scholar
• Popper KR (1959) The logic of scientific discovery. Basic, New York
  Google Scholar
• Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O’Malley SS, Wong CJ (2016) Proof-of-concept study to assess the nociceptin receptor antagonist LY2940094 as a new treatment for alcohol dependence. Alcohol Clin Exp Res 40(9):1935–1944
  CAS PubMed Google Scholar
• Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, Dale TM, Penick EC, Samuelson SD, Lacoursiere RB (1995) A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res 19(2):462–468
  CAS PubMed Google Scholar
• Pratley RE, Gilbert M (2008) Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 5(2):73–94
  PubMed PubMed Central Google Scholar
• Quadros IM, Hwa LS, Shimamoto A, Carlson J, DeBold JF, Miczek KA (2014) Prevention of alcohol-heightened aggression by CRF-R1 antagonists in mice: critical role for DRN-PFC serotonin pathway. Neuropsychopharmacology 39(12):2874–2883
  CAS PubMed PubMed Central Google Scholar
• Quadros IM, Macedo GC, Domingues LP, Favoretto CA (2016) An update on CRF mechanisms underlying alcohol use disorders and dependence. Front Endocrinol (Lausanne) 7:134
  Google Scholar
• Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW (2000) Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res 24(12):1836–1849
  CAS PubMed Google Scholar
• Ray LA, Mackillop J, Leggio L, Morgan M, Hutchison KE (2009) Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol Biochem Behav 91(4):489–494
  CAS PubMed Google Scholar
• Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K (2017a) Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology 42(9):1776–1788
  CAS PubMed PubMed Central Google Scholar
• Ray LA, Bujarski S, Yardley MM, Roche DJO, Hartwell EE (2017b) Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? Am J Drug Alcohol Abuse 20:1–8
  Google Scholar
• Redish AD, Gordon JA (2016) Computational psychiatry: new perspectives on mental illness. MIT Press, Cambridge
  Google Scholar
• Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270(5237):792–794
  CAS PubMed Google Scholar
• Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients – the ALPADIR study. Alcohol Alcohol 52(4):439–446
  CAS PubMed Google Scholar
• Richardson HN, Lee SY, O’Dell LE, Koob GF, Rivier CL (2008) Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. Eur J Neurosci 28(8):1641–1653
  PubMed PubMed Central Google Scholar
• Richter SH, Garner JP, Würbel H (2009) Environmental standardization: cure or cause of poor reproducibility in animal experiments? Nat Methods 6(4):257–261
  CAS PubMed Google Scholar
• Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Förg A, Volkmar K, Glauner T, Schaefer M (2012) Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 32(4):558–562
  CAS PubMed Google Scholar
• Roberto M, Siggins GR (2006) Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala. Proc Natl Acad Sci U S A 103(25):9715–9720
  CAS PubMed PubMed Central Google Scholar
• Roberto M, Gilpin NW, O’Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF (2008) Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci 28(22):5762–5771
  CAS PubMed Google Scholar
• Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, Cottone P, Madamba SG, Stouffer DG, Zorrilla EP, Koob GF, Siggins GR, Parsons LH (2010) Corticotropin releasing factor-induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol Psychiatry 67(9):831–839
  CAS PubMed PubMed Central Google Scholar
• Roberto M, Patel RR, Bajo M (2018) Ethanol and cytokines in the central nervous system. Handb Exp Pharmacol. https://doi.org/10.1007/164_2017_77
• Robinson G, Most D, Ferguson LB, Mayfield J, Harris RA, Blednov YA (2014) Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. Int Rev Neurobiol 118:13–39
  PubMed PubMed Central Google Scholar
• Rodi D, Zucchini S, Simonato M, Cifani C, Massi M, Polidori C (2008) Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology 196(4):523–531
  CAS PubMed Google Scholar
• Rohn MC, Lee MR, Kleuter SB, Schwandt ML, Falk DE, Leggio L (2017) Differences between treatment-seeking and nontreatment-seeking alcohol-dependent research participants: an exploratory analysis. Alcohol Clin Exp Res 41(2):414–420
  PubMed Google Scholar
• Roltsch EA, Baynes BB, Mayeux JP, Whitaker AM, Baiamonte BA, Gilpin NW (2014) Predator odor stress alters corticotropin-releasing factor-1 receptor (CRF1R)-dependent behaviors in rats. Neuropharmacology 79:83–89
  CAS PubMed Google Scholar
• Romach MK, Sellers EM, Kaplan HL, Somer GR, Gomez-Mancilla B (2000) Efficacy of dexfenfluramine in the treatment of alcohol dependence. Alcohol Clin Exp Res 24:1534–1541
  CAS PubMed Google Scholar
• Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Weiss F, Statnick MA (2016) A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol seeking in animal models. Alcohol Clin Exp Res 40(5):945–954
  CAS PubMed PubMed Central Google Scholar
• Rose AK, Shaw SG, Prendergast MA, Little HJ (2010) The importance of glucocorticoids in alcohol dependence and neurotoxicity. Alcohol Clin Exp Res 34(12):2011–2018
  CAS PubMed PubMed Central Google Scholar
• Rotter A, Biermann T, Amato D, Schumann G, Desrivieres S, Kornhuber J, Müller CP (2012) Glucocorticoid receptor antagonism blocks ethanol-induced place preference learning in mice and attenuates dopamine D2 receptor adaptation in the frontal cortex. Brain Res Bull 88(5):519–524
  CAS PubMed Google Scholar
• Ruse M (1973) The nature of scientific models: formal v. material analogy. Phil Soc Sci 3:63–80
  Google Scholar
• Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ (2017) A phase2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology 42:1012–1023
  CAS PubMed Google Scholar
• Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P (2013) mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res 15(247):9–16
  Google Scholar
• Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H, Anton RF (2017) Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology 42(13):2640–2653
  CAS PubMed PubMed Central Google Scholar
• Schreiber AL, Gilpin NW (2018) Corticotropin-releasing factor (CRF) neurocircuitry and neuropharmacology in alcohol drinking. Handb Exp Pharmacol (in press)
  Google Scholar
• Schwandt ML, Lindell SG, Higley JD, Suomi SJ, Heilig M, Barr CS (2011) OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques. Psychoneuroendocrinology 36(9):1303–1311
  CAS PubMed PubMed Central Google Scholar
• Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, Heilig M (2016) The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology 41(12):2818–2829
  CAS PubMed PubMed Central Google Scholar
• Scuppa G, Cippitelli A, Toll L, Ciccocioppo R, Ubaldi M (2015) Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. Drug Alcohol Depend 156:126–132
  CAS PubMed PubMed Central Google Scholar
• Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18:879–885
  CAS PubMed Google Scholar
• Shirazi RH, Dickson SL, Skibicka KP (2013) Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One 8(4):e61965
  CAS PubMed PubMed Central Google Scholar
• Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE (2012) Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology 37(4):906–918
  CAS PubMed Google Scholar
• Skinner BF (1959) In: Cole JO, Girard RW (eds) Psychopharmacology: problems in evaluation. National Academy of Sciences, Washington, pp 224–235
  Google Scholar
• Skinner MD, Lahmek P, Pham H, Aubin HJ (2014) Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 9(2):e87366
  PubMed PubMed Central Google Scholar
• Somkuwar SS, Vendruscolo LF, Fannon MJ, Schmeichel BE, Nguyen TB, Guevara J, Sidhu H, Contet C, Zorrilla EP, Mandyam CD (2017) Abstinence from prolonged ethanol exposure affects plasma corticosterone, glucocorticoid receptor signaling and stress-related behaviors. Psychoneuroendocrinology 84:17–31
  CAS PubMed PubMed Central Google Scholar
• Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS, Heilig MA (2008) Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 63(2):139–145
  PubMed Google Scholar
• Sørensen G, Caine SB, Thomsen M (2016) Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin Exp Res 40(10):2247–2252
  PubMed PubMed Central Google Scholar
• Sotomayor-Zarate R, Gysling K, Busto UE, Cassels BK, Tampier L, Quintanilla ME (2013) Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats. Psychopharmacology 227:287–298
  CAS PubMed Google Scholar
• Spagnolo PA, Colloca L, Heilig M (2015) The role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments. Alcohol Alcohol 50(3):282–285
  PubMed PubMed Central Google Scholar
• Sparta DR, Hopf FW, Gibb SL, Cho SL, Stuber GD, Messing RO, Ron D, Bonci A (2013) Binge ethanol-drinking potentiates corticotropin releasing factor R1 receptor activity in the ventral tegmental area. Alcohol Clin Exp Res 37(10):1680–1687
  CAS PubMed PubMed Central Google Scholar
• Spierling SR, Zorrilla EP (2017) Don’t stress about CRF: assessing the translational failures of CRF(1)antagonists. Psychopharmacology 234(9–10):1467–1481
  CAS PubMed PubMed Central Google Scholar
• Sprow GM, Thiele TE (2012) The neurobiology of binge-like ethanol drinking: evidence from rodent models. Physiol Behav 106(3):325–331
  CAS PubMed PubMed Central Google Scholar
• Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104:12518–12523
  CAS PubMed PubMed Central Google Scholar
• Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, Jerlhag E, Engel JA, Hodgkinson CA, Egli M, Lopez MF, Becker HC, Goldman D, Heilig M, Ramchandani VA, Leggio L (2015) The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 5(6):e583. https://doi.org/10.1038/tp.2015.68
  Article CAS PubMed PubMed Central Google Scholar
• Tabakoff B, Jafee RC, Ritzmann RF (1978) Corticosterone concentrations in mice during ethanol drinking and withdrawal. J Pharm Pharmacol 30(6):371–374
  CAS PubMed Google Scholar
• Thomsen M, Dencker D, Wörtwein G, Weikop P, Egecioglu E, Jerlhag E, Fink-Jensen A, Molander A (2017) The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol Biochem Behav 160:14–20
  CAS PubMed Google Scholar
• Tomkins DM, Le AD, Sellers EM (1995) Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology 117(4):479–485
  CAS PubMed Google Scholar
• Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, Liu XA, Lu Q, Cameron M, Hayes MR, Kamenecka TM, Pletcher M, Kenny PJ (2017) GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci 20(5):708–716
  CAS PubMed PubMed Central Google Scholar
• Tunstall BJ, Carmack SA, Koob GF, Vendruscolo LF (2017) Dysregulation of brain stress systems mediates compulsive alcohol drinking. Curr Opin Behav Sci 13:85–90
  PubMed Google Scholar
• Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, Engel JA, Jerlhag E (2016) The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 21(2):422–437
  PubMed Google Scholar
• Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr, Logrip ML, Rivier C, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Heilig M, Koob GF (2012) Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32(22):7563–7571
  CAS PubMed PubMed Central Google Scholar
• Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ (2015) Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest 125(8):3193–3197
  PubMed PubMed Central Google Scholar
• Vengeliene V, Olevska A, Spanagel R (2015) Long-lasting effect of NMDA receptor antagonist memantine on ethanol-cue association and relapse. J Neurochem 135(6):1080–1085
  CAS PubMed Google Scholar
• Vitale G, Arletti R, Ruggieri V, Cifani C, Massi M (2006) Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats. Peptides 27(9):2193–2200
  CAS PubMed Google Scholar
• Wagenmakers E-J, Wetzels R, Borsboom D, van der Maas HLJ, Kievet RA (2012) An agenda for purely confirmatory research. Perspect Psychol Sci 7:632–638
  PubMed Google Scholar
• Walker BM, Koob GF (2007) The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res 31:11–18
  CAS PubMed PubMed Central Google Scholar
• Wand GS, Dobs AS (1991) Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. J Clin Endocrinol Metab 72(6):1290–1295
  CAS PubMed Google Scholar
• Weiss F, Mitchiner M, Bloom FE, Koob GF (1990) Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology 101(2):178–186
  CAS PubMed Google Scholar
• Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, Zhang HT, Liang JH (2012) The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases EtOH seeking and consumption in alcohol preferring fawn-hooded rats. Alcohol Clin Exp Res 36:2157–2167
  CAS PubMed PubMed Central Google Scholar
• Wen RT, Feng WY, Liang JH, Zhang HT (2015) Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence. Curr Pharm Des 21(3):355–364
  CAS PubMed Google Scholar
• Wiesbeck GA, Weijers HG, Chick J, Naranjo CA, Boening J (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 23(2):230–235
  CAS PubMed Google Scholar
• Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol 36(4):329–334
  CAS PubMed Google Scholar
• Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, Litten RZ, O’Malley SS, Anton RF (2017) Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res 41(1):179–186
  PubMed Google Scholar
• Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R (2014) The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141(3):283–299
  CAS PubMed Google Scholar
• Wolstenholme JT, Warner JA, Capparuccini MI, Archer KJ, Shelton KL, Miles MF (2011) Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice. PLoS One 6(6):e21100
  CAS PubMed PubMed Central Google Scholar
• Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ (2014) A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res 38(2):511–520
  CAS PubMed Google Scholar
• Wouda JA, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D, Schoffelmeer ANM, Pattij T, De Vries TJ (2011) Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology 216:267–277
  CAS PubMed PubMed Central Google Scholar
• Yardley MM, Ray LA (2017) Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol 22(3):581–615
  PubMed Google Scholar
• Yoshimura A, Kimura M, Nakayama H, Matsui T, Okudaira F, Akazawa S, Ohkawara M, Cho T, Kono Y, Hashimoto K, Kumagai M, Sahashi Y, Roh S, Higuchi S (2014) Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res 38(2):572–578
  CAS PubMed Google Scholar
• Zalewska-Kaszubska J, Bajer B, Czarnecka E, Dyr W, Gorska D (2011) Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study. Physiol Behav 102(5):538–541
  CAS PubMed Google Scholar
• Zhou Y, Colombo G, Carai MA, Ho A, Gessa GL, Kreek MJ (2011) Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res 35(10):1876–1883
  CAS PubMed PubMed Central Google Scholar
• Zorrilla EP, Logrip ML, Koob GF (2014) Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol 35(2):234–244
  CAS PubMed PubMed Central Google Scholar

Download references